# Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

> **NCT05098132** · PHASE1,PHASE2 · RECRUITING · sponsor: **Synthekine** · enrollment: 364 (estimated)

## Conditions studied

- Advanced Solid Tumor
- Non Small Cell Lung Cancer
- Untreated Advanced NSCLC
- 1st Line NSCLC

## Interventions

- **DRUG:** STK-012
- **DRUG:** pembrolizumab
- **DRUG:** pemetrexed
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT05098132
- **Lead sponsor:** Synthekine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-25
- **Primary completion:** 2029-01
- **Final completion:** 2029-01
- **Target enrollment:** 364 (ESTIMATED)
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098132, "Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05098132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*